趋化素受体是能与趋化素特异性结合的一类膜受体,属于 G 蛋白偶联受体家族,归类为 Class A。目前趋化素受体主要有趋化素受体 1,也称为 ChemR23 或 CMKLR1 和趋化素受体 2 ,也称为 GPR1。趋化素与其受体结合后,可招募并激活免疫细胞,增强机体的固有免疫和适应性免疫反应。同时,也可以调节血管内皮细胞的功能,促进血管生成。趋化素受体也参与能量代谢和脂肪组织的调节。趋化素及其受体表达和功能的异常与肿瘤、炎症性疾病和肥胖、糖尿病等代谢性疾病密切相关[1][2]。
Chemerin receptors are a type of membrane receptors that can specifically bind to chemerin and belong to the G-protein-coupled receptor family Class A. Currently, the main chemerin receptors include chemerin receptor 1, also known as ChemR23 or CMKLR1, and chemerin receptor 2, also known as GPR1. After chemerin binds to its receptor, it can recruit and activate immune cells, enhancing the body's innate and adaptive immune responses. At the same time, it can also regulate the functions of vascular endothelial cells and promote angiogenesis. Chemerin receptors are also involved in the regulation of energy metabolism and adipose tissue. Abnormalities in the expression and function of chemerin and its receptors are closely related to cancer, inflammatory diseases, and metabolic diseases such as obesity and diabetes[1][2].
ChemR23-IN-4(Compound 13)是一种有效的、具有口服活性的 ChemR23 抑制剂,其对人类 ChemR23 的 IC50 为 17 nM。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号